Navigation Links
Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Date:6/6/2008

ls of plasma and urinary isoprostanes, CRP, myeloperoxidase, paraoxonase and other markers of inflammation or oxidative stress.

Trial 203 was a Phase 2, placebo-controlled study evaluating 40mg of SYI-2074 administered three times daily for two days in diabetic patients undergoing angioplasty. The primary endpoint of the study was reduction of the amount of heart muscle enzyme (CK-MB) released from the heart as a consequence of the procedure. Results showed that there was no significant reduction in CK-MB, which indicates that the normal damage to heart muscle following an angioplasty occurred during the procedure regardless of the administration of SYI-2074.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit inflammation related to oxidative stress. It currently plans a program in psoriasis with its lead compound. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes. It is also developing a kit to measure CML, another potential cardiovascular risk marker.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failu
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
2. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
3. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
6. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Percutaneous Administration (CUPID) Data Highlight Safety Profile and ... 26 Celladon Corporation today announced that results ... advanced heart failure, including Phase 1/2 data of ... Zsebo, PhD, President and CEO, Celladon Corporation and ...
... 26 Senesco Technologies, Inc. ("Senesco" or the "Company") ... mouse influenza survival studies that were conducted in Dr. William Scheld,s ... Mice treated with an siRNA against Senesco,s Factor 5A gene ... rate for mice that received no treatment or a control siRNA.A ...
Cached Medicine Technology:Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... last week could significantly increase the success rate of ... has indicated that rejection of animal cells and organs ... the presence of the gene alpha 1,3 galactosyl transferase. ... sugar// to the surface of pig cells, flagging them ...
... heart arteries flowing easily after angioplasty shows fantastic success ... the common procedure.Doctors released the longest follow up ... testing on 30 patients over three years, they found ... unheard of in medicine.// ,More than 1 million ...
... Using modern brain imaging techniques, scientists have indicated the ... are going to be stored or deleted. The study ... of Technology (MIT) and reported to the American Association ... ,The researchers coupled a number of different ...
... more precise predictions of a person's risk of a fatal ... journal suggested the test, which measures levels of the protein ... trouble than traditional cholesterol tests and may one day lead ... of the strongest risk factors for developing coronary artery disease ...
... will probably have to depend on current anthrax vaccines ... Second-generation vaccines are in the works but not ready. ... to go, approved by the FDA.// ,The government ... anthrax vaccine to resume shipping after four years in ...
... lines could aggregate genetic abnormalities over time and new ... Dr.Vogelstein, chairman of a key stem cell research committee ... the current stem cell lines are problematic because ... cell divide in a tissue culture it accumulates mutations. ...
Cached Medicine News:Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2Health News:Blood Test May help Heart Prediction 2Health News:New Stem Cells lines will be required 2
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
Medicine Products: